Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Omer Shvili who wrote (1377)	10/9/1998 10:55:00 PM
From: NeuroInvestment	Read Replies (3) of 1491

I agree that the 'HU211 triples likelihood of good outcome in severe head injury' headline was what was missing from the release--and I spoke to management yesterday about that element. It does appear that management and RuderFinn are still trying to get into 'synch' on how to present clinical data. However, I am not convinced that any headline was going to make a big difference in the stock price given the smallcap bloodletting. The fact that there was no apparent difference between dose level cohorts also means that there is little reason to expect anything from the 200mg group that is beyond what we have seen; which means that there is no cogent reason for Pharmos and the various Big Pharma companies interested in HU211 to wait for that final cohort to be finished; I have no doubt that several companies were looking at the data under a confidentiality agreement since a couple of weeks past, and now the number of companies involved should increase.With the magnitude of effect established, and clinical proof of principle confirmed--and safety maintained--negotiations should be able to begin in earnest in the near future. NeuroInvestment (www.neuroinv.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next